Emergent Biosolutions (NYSE:EBS)‘s stock had its “buy” rating reissued by analysts at Cantor Fitzgerald in a research note issued to investors on Sunday, AnalystRatings.com reports. They currently have a $75.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 41.62% from the stock’s current price.
The analysts wrote, “As investors appreciate the durability and revenue potential of Emergent’s portfolio, we expect upward earnings revisions and multiple expansion to drive the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $75. The Disclosure Section may be found on pages 3 – 5.Valuation We use a blend of DCF and EV/EBITDA to get to our PT of $75.””
EBS has been the subject of a number of other reports. Wells Fargo & Co set a $68.00 target price on shares of Emergent Biosolutions and gave the company a “hold” rating in a research report on Friday, March 1st. Zacks Investment Research downgraded shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research report on Thursday, January 3rd. ValuEngine downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. TheStreet downgraded shares of Emergent Biosolutions from a “b+” rating to a “c+” rating in a research report on Tuesday, March 12th. Finally, Chardan Capital set a $71.00 target price on shares of Emergent Biosolutions and gave the company a “buy” rating in a research report on Friday, February 22nd. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $70.43.
Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, February 21st. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.14. Emergent Biosolutions had a net margin of 8.02% and a return on equity of 12.61%. The firm had revenue of $270.70 million during the quarter, compared to the consensus estimate of $269.05 million. During the same period in the prior year, the firm earned $0.74 EPS. The company’s revenue was up 39.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Emergent Biosolutions will post 3.15 earnings per share for the current year.
In related news, EVP Adam Havey sold 3,043 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $58.11, for a total value of $176,828.73. Following the completion of the transaction, the executive vice president now directly owns 36,694 shares of the company’s stock, valued at approximately $2,132,288.34. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Daniel Abdun-Nabi sold 14,565 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $58.11, for a total transaction of $846,372.15. Following the completion of the transaction, the chief executive officer now directly owns 142,617 shares of the company’s stock, valued at $8,287,473.87. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 58,132 shares of company stock valued at $3,411,113. 14.10% of the stock is owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rehmann Capital Advisory Group boosted its holdings in Emergent Biosolutions by 78.7% in the 4th quarter. Rehmann Capital Advisory Group now owns 452 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 199 shares during the period. Quantamental Technologies LLC purchased a new stake in Emergent Biosolutions in the 4th quarter worth approximately $29,000. Semmax Financial Advisors Inc. purchased a new stake in Emergent Biosolutions in the 4th quarter worth approximately $30,000. Bronfman E.L. Rothschild L.P. lifted its stake in Emergent Biosolutions by 1,108.7% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 1,112 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 1,020 shares in the last quarter. Finally, First Hawaiian Bank lifted its stake in Emergent Biosolutions by 78.0% in the 1st quarter. First Hawaiian Bank now owns 1,394 shares of the biopharmaceutical company’s stock worth $70,000 after purchasing an additional 611 shares in the last quarter. 84.61% of the stock is owned by institutional investors.
About Emergent Biosolutions
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.
Read More: Google Finance
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.